AKT in cancer: new molecular insights and advances in drug development

por Mundi, Prabhjot S., Sachdev, Jasgit, McCourt, Carolyn, Kalinsky, Kevin
Publicado no Br J Clin Pharmacol (2016)

Does Race Affect Outcomes in Triple Negative Breast Cancer?

por Sachdev, Jasgit C., Ahmed, Saira, Mirza, Muhammad M., Farooq, Aamer, Kronish, Lori, Jahanzeb, Mohammad
Publicado em 2010

Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors

por Beg, Muhammad S., Brenner, Andrew J., Sachdev, Jasgit, Borad, Mitesh, Kang, Yoon-Koo, Stoudemire, Jay, Smith, Susan, Bader, Andreas G., Kim, Sinil, Hong, David S.
Publicado no Invest New Drugs (2016)

TRLS-06. PHASE 1 EXPANSION STUDY OF IRINOTECAN LIPOSOME INJECTION (nal-IRI) IN PATIENTS WITH METASTATIC BREAST CANCER (mBC): FINDINGS FROM THE COHORT WITH ACTIVE BRAIN METASTASIS (...

por Anders, Carey, Munster, Pamela, Northfelt, Donald, Han, Hyo Sook, Ma, Cynthia, Maxwell, Fiona, Wang, Tiffany, Belanger, Bruce, Zhang, Bin, Moore, Yan, Sachdev, Jasgit C
Publicado no Neurooncol Adv (2019)

Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase

por Sachdev, Jasgit C., Munster, Pamela, Northfelt, Donald W., Han, Hyo Sook, Ma, Cynthia, Maxwell, Fiona, Wang, Tiffany, Belanger, Bruce, Zhang, Bin, Moore, Yan, Thiagalingam, Arunthathi, Anders, Carey
Publicado no Breast Cancer Res Treat (2020)

Safety and pharmacokinetics of veliparib extended‐release in patients with advanced solid tumors: a phase I study

por Werner, Theresa L., Sachdev, Jasgit, Swisher, Elizabeth M., Gutierrez, Martin, Kittaneh, Muaiad, Stein, Mark N., Xiong, Hao, Dunbar, Martin, Sullivan, Danielle, Komarnitsky, Philip, McKee, Mark, Tan, Antoinette R.
Publicado no Cancer Med (2018)

Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours

por Mahalingam, Devalingam, Patel, Manish R., Sachdev, Jasgit C., Hart, Lowell L., Halama, Niels, Ramanathan, Ramesh K., Sarantopoulos, John, Völkel, Dirk, Youssef, Ashraf, de Jong, Floris A., Tsimberidou, Apostolia Maria
Publicado no Br J Clin Pharmacol (2020)

A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas

por Lin, Chia-Chi, Arkenau, Hendrik-Tobias, Lu, Sharon, Sachdev, Jasgit, de Castro Carpeño, Javier, Mita, Monica, Dziadziuszko, Rafal, Su, Wu-Chou, Bobilev, Dmitri, Hughes, Lorraine, Chan, Jian, Zhang, Zhi-Yi, Weiss, Glen J.
Publicado no Br J Cancer (2019)

Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers

por de Bono, Johann, Ramanathan, Ramesh K., Mina, Lida, Chugh, Rashmi, Glaspy, John, Rafii, Saeed, Kaye, Stan, Sachdev, Jasgit, Heymach, John, Smith, David C., Henshaw, Joshua W., Herriott, Ashleigh, Patterson, Miranda, Curtin, Nicola J., Byers, Lauren Averett, Wainberg, Zev A.
Publicado no Cancer Discov (2017)

Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours

por Hong, David S., Kang, Yoon-Koo, Borad, Mitesh, Sachdev, Jasgit, Ejadi, Samuel, Lim, Ho Yeong, Brenner, Andrew J., Park, Keunchil, Lee, Jae-Lyun, Kim, Tae-You, Shin, Sangjoon, Becerra, Carlos R., Falchook, Gerald, Stoudemire, Jay, Martin, Desiree, Kelnar, Kevin, Peltier, Heidi, Bonato, Vinicius, Bader, Andreas G., Smith, Susan, Kim, Sinil, O’Neill, Vincent, Beg, Muhammad S.
Publicado no Br J Cancer (2020)

Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial

por Kalinsky, Kevin, Hong, Fangxin, McCourt, Carolyn K., Sachdev, Jasgit C., Mitchell, Edith P., Zwiebel, James A., Doyle, L. Austin, McShane, Lisa M., Li, Shuli, Gray, Robert J., Rubinstein, Larry V., Patton, David, Williams, Paul M., Hamilton, Stanley R., Conley, Barbara A., O’Dwyer, Peter J., Harris, Lyndsay N., Arteaga, Carlos L., Chen, Alice P., Flaherty, Keith T.
Publicado no JAMA Oncol (2020)

Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma

por Konstantinopoulos, Panagiotis A., Waggoner, Steven, Vidal, Gregory A., Mita, Monica, Moroney, John W., Holloway, Robert, Van Le, Linda, Sachdev, Jasgit C., Chapman-Davis, Eloise, Colon-Otero, Gerardo, Penson, Richard T., Matulonis, Ursula A., Kim, Young Bae, Moore, Kathleen N., Swisher, Elizabeth M., Färkkilä, Anniina, D’Andrea, Alan, Stringer-Reasor, Erica, Wang, Jing, Buerstatte, Nathan, Arora, Sujata, Graham, Julie R., Bobilev, Dmitri, Dezube, Bruce J., Munster, Pamela
Publicado no JAMA Oncol (2019)

Hepatobiliary Cancers: Clinical Practice Guidelines in Oncology™

por Benson, Al B., Abrams, Thomas A., Ben-Josef, Edgar, Bloomston, P. Mark, Botha, Jean F., Clary, Bryan M., Covey, Anne, Curley, Steven A., D'Angelica, Michael I., Davila, Rene, Ensminger, William D., Gibbs, John F., Laheru, Daniel, Malafa, Mokenge P., Marrero, Jorge, Meranze, Steven G., Mulvihill, Sean J., Park, James O., Posey, James A., Sachdev, Jasgit, Salem, Riad, Sigurdson, Elin R., Sofocleous, Constantinos, Vauthey, Jean-Nicolas, Venook, Alan P., Goff, Laura Williams, Yen, Yun, Zhu, Andrew X.
Publicado no J Natl Compr Canc Netw (2009)